The U.S. Food and Drug Administration (FDA) has issued a draft guidance for the development of implantable brain-computer interface (BCI) devices. The goal is to help patients suffering from paralysis or missing limbs regain mobility.
In his press statement released on February 22, FDA Commissioner Scott Gottlieb, M.D., commented that “BCI devices hold the potential for direct control of, for example, a limb prosthesis by the patient’s thought processes. This can allow significantly greater mobility and independence for patients. These devices have the potential to benefit people with severe disabilities by increasing their ability to interact with their environment. This is a critical area of development for the millions of people who suffer from conditions that inhibit their mobility.”
Several online cialis on sale reports have been published in numerous parts of globe that imply that Himalaya herbal products are good to improve length and girth of erection in men. cialis without prescriptions canada How to spice up your relationship In most long-term relationships, the intimacy and passion can begin to wane as time goes on. There have been several recordings of a device known as the electreat, among other viagra without prescription usa http://miamistonecrabs.com/category/shop/ such devices that were used for treating men with erectile dysfunction condition. Prior to that, a woman must know that women’s sexual desires vary greatly. viagra generico cialis miamistonecrabs.com Among other steps, the FDA has assembled an Emerging Sciences Working Group, a team of 15 FDA experts whose task will be to actively look for future innovations. In addition, the FDA is also committed to collaborating with stakeholders, including product developers in the private sector, to advance the field of brain-computer interaction.
The FDA is encouraging stakeholders to provide feedback on the new draft guidance to ensure that all viewpoints are considered as the FDA finalizes the guidance to improve and facilitate development of BCI devices. “Working together with researchers, developers, patients and providers, our aim is to advance policies that encourage more novel therapies that can dramatically alter the trajectory of health and mobility,” Gottlieb concluded.